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Macrophage inhibitory cytokine-1 (MIC-1) gene is a member of transforming growth factor-b superfamily and was reported to be
highly overexpressed in human prostate cancer using microarray technology. The aim of this study was to evaluate the quantitative
expression of MIC-1 in malignant and benign prostate tissues and to associate expression levels with clinicopathological parameters of
prostate cancer. Matched (paired) prostatic tissue samples from the cancerous and noncancerous parts of the same prostates were
obtained from 66 patients who underwent radical prostatectomy. Quantitative RT–PCR was performed using SYBR Green I on the
Roche LightCycler
TM system. Macrophage inhibitory cytokine-1 gene overexpression in cancerous tissues was observed in 88% of
cases, compared to noncancerous tissues (Po0.001). The expression level of MIC-1 in cancerous tissues was significantly higher than
in noncancerous tissue (Po0.001). Higher expression of MIC-1 gene was significantly associated with higher Gleason score
(P¼0.004). The expression of the MIC-1 gene in prostate cancer is significantly higher than in noncancerous tissues, especially in
more aggressive forms of the disease (Gleason score45). This is in contrast to prostate-specific antigen that is downregulated in
higher-grade tumours. The upregulation of MIC-1 in prostate cancer and in advanced and more aggressive prostatic tumours suggests
that MIC-1 protein should be evaluated as a potential diagnostic and prognostic biomarker.
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Prostate cancer is the most common cancer of North American
men. Prostate-specific antigen (PSA), also known as human
kallikrein 3 (hK3), according to the approved new nomenclature
of the human kallikrein family (Diamandis et al, 2000a), is used for
early detection and monitoring of prostate cancer (Bilhartz et al,
1991; Oesterling, 1991; Diamandis et al, 2000b). However,
nonmalignant prostatic diseases, especially benign prostatic
hyperplasia (BPH) and acute prostatitis, also cause serum PSA
elevation, thus complicating the diagnosis of prostatic cancer by
PSA measurements alone (Polascik et al, 1999). The evaluation of
the molecular forms of PSA improves the specificity of PSA
(Mitchell et al, 2001; Stephan et al, 2002). Despite the availability of
these tests, there is an urgent need for new biomarkers for early
detection of prostate cancer. In accordance with the principles of
the development of new biomarkers (Sullivan Pepe et al, 2001), one
approach would be to search for genes that are overexpressed in
prostate cancer.
The macrophage inhibitory cytokine-1 (MIC-1) gene is a
member of transforming growth factor-b (TGF-b) superfamily
and was originally isolated from macrophages using the cDNA
subtraction method (Bootcov et al, 1997). The macrophage
inhibitory cytokine-1 gene is also known as growth/differentiation
factor-15 (Bottner et al, 1999) and placental bone morphogenetic
protein (PLAB) (Hromas et al, 1997; Thomas et al, 2001). Recent
reports, using DNA microarray technology, have shown that the
MIC-1 gene is more highly expressed in prostate cancer than in
BPH tissues (Buckhaults et al, 2001; Welsh et al, 2001). Until now,
there are no quantitative expression data on relatively large groups
of patients.
The aim of this study was to investigate the expression of MIC-1
in cancerous and matched noncancerous prostate tissues by
quantitative RT–PCR and associate these data with clinicopatho-
logical parameters of prostate cancer patients.
MATERIALS AND METHODS
Study group
Included in this study were 66 patients who had undergone radical
retropubic prostatectomy for prostatic adenocarcinoma at the
Charite ´ University Hospital, Berlin, Germany. Patient ages ranged
from 48 to 73 years with a mean of 62.7 and a median of 64 years.
The patients did not receive any hormonal or other therapy before
surgery.
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Fresh prostate tissue samples were obtained from the cancerous
and noncancerous parts of the same prostates. Small pieces of
tissue were gross dissected by an experienced pathologist
(GK) immediately after removal of the prostate, snap frozen and
stored in liquid nitrogen until analysis, as described previously
(Meyer et al, 1997). Histological analysis of paraffin-embedded
tissue adjacent to these samples was performed by the same
pathologist to verify the diagnoses. Only tumour samples that
were fully surrounded by malignant tissue according to this
analysis were used in this study. We also discarded samples in
which benign prostate glands made up more than 10% of the
tissue. This way, we minimised the contamination of the tumour
sample with benign glands, which is not fully avoidable in
prostate cancer unless microdissected tissues were processed. Most
of the tumours were located dorsolaterally in the peripheral zone
of the prostate. The tissue that we considered as normal was
usually taken from the inner zone of the contralateral lobe.
Histologically, many of these samples displayed a mild glandular
hyperplasia. The criteria of exclusion were prominent inflamma-
tory infiltrates, lack of epithelia due to stromal hyperplasia and
prostatic intraepithelial neoplasia. The Ethics Committee of the
Charite Hospital approved the use of these tissues for research
purposes.
Total RNA extraction and cDNA synthesis
Tumour tissues were minced with a scalpel, on dry ice, and
transferred immediately to 2ml polypropylene tubes. They were
then homogenised and total RNA was extracted using the RNeasy
s
total RNA isolation system, following the manufacturer’s instruc-
tions (Qiagen, Valencia, CA, USA). The concentration and purity
of RNA were determined spectrophotometrically. Two micrograms
of total RNA were reverse-transcribed into first strand cDNA using
the Superscript
TM preamplification system (Gibco BRL, Gaithers-
burg, MD, USA). The final volume was 20ml.
Quantitative real-time RT–PCR analysis
Two gene-specific primers were designed (MIC-1/F: 50 CGC GCA
ACG GGG ACG ACT 30 and MIC-1/R: 50 TGA GC ACC ATG GGA
TTG TAG C 3011). Real-time monitoring of PCR reactions was
performed using the LightCycler
TM system (RocheApplied Science,
Indianapolis, IN, USA) and the SYBR green I dye, which binds
preferentially to double-stranded DNA. Fluorescence signals,
which are proportional to the concentration of the PCR product,
are measured at the end of each cycle and displayed on a computer
screen (Buckhaults et al, 2001). The reaction is characterised by
the point during cycling when amplification of PCR products is
first detected, rather than the amount of PCR product accumulated
after a fixed number of cycles. The higher the starting quantity of
the template, the earlier a significant increase in fluorescence is
observed (Wittwer et al, 1997; Bieche et al, 1999). The threshold
cycle is defined as the fractional cycle number at which
fluorescence passes a fixed threshold above baseline (Bieche et al,
1998).
Endogenous control
For each sample, the amount of the target and of b actin, as an
endogenous control, was determined using a calibration curve. The
amount of the target molecule was then divided by the amount of
the endogenous reference, to obtain a normalised target value
(Bieche et al, 1999).
Calibration curves
Separate calibration (standard) curves for actin and MIC-1 were
constructed using serial dilutions of total cDNA from a healthy
human prostate tissue, purchased from Clontech, Palo Alto, CA,
USA. The standard curve samples were included in each run.
Standards for both MIC-1 and actin RNAs were defined to contain
an arbitrary starting concentration, since no primary calibrators
exist. Hence, all calculated concentrations are relative to the
concentration of the standard.
PCR amplification
The PCR reaction was carried out on the LightCycler
TM system.
For each run, a master mixture was prepared on ice, containing
1ml of cDNA, 2ml of LC DNA Master SYBR Green I mix, 50ng of
primers and 2.4mlo f2 5m M MgCl2. The final volume was adjusted
with H2Ot o2 0 ml. After the reaction mixture was loaded into a
glass capillary tube, the cycling conditions were carried out as
follows: initial denaturation at 951C for 10min, followed by 42
cycles of denaturation at 951C for 1s, annealing at 581C for 8s and
extension at 721C for 30s. The temperature transition rate was set
at 201Cs
 1. Fluorescent product was measured by a single
acquisition mode at 921C after each cycle.
Melting curve
For distinguishing specific from nonspecific products and primer
dimers, a melting curve was obtained after amplification by
holding the temperature at 701C for 30s followed by a gradual
increase in temperature to 991C at a rate of 0.21Cs
 1, with the
signal acquisition mode set at step, as described. To verify the
melting curve results, representative samples of the PCR products
were run on 1.5% agarose gels, purified, and cloned into the pCR
2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. The inserts were sequenced from both
directions using vector-specific primers, with an automated DNA
sequencer.
Statistical analysis
Statistical analysis was performed with SAS software (SAS
Institute, Cary, NC, USA). The analyses of differences between
MIC-1 expression in noncancerous and cancerous tissues were
performed with the nonparametric McNemar test and the
Wilcoxon signed ranks test. The binomial distribution was used
to compute the significance level of the McNemar test. Relations
between different variables were assessed by the Mann–Whitney
U-test.
RESULTS
Expression level of MIC-1 in prostatic tissues
We assessed the quantitative expression of MIC-1 mRNA in the 66
matched pairs of cancerous and noncancerous prostatic tissues.
The expression levels of MIC-1 were expressed in arbitrary units,
according to a standard curve that was constructed by using serial
dilutions of a cDNA obtained from normal prostatic tissue. Results
were then normalised by using the ratio of MIC-1/b-actin
concentration for each sample.
Fifty eight cases showed higher expression level of MIC-1 gene
in cancerous prostatic tissues in comparison with noncancerous
tissues. Lower expression in cancer was observed in only eight
cases. This difference was statistically significant (Po0.001)
(Table 1 and Figure 1). The expression levels of MIC-1 gene in
cancerous prostatic tissues were significantly higher than that in
noncancerous prostatic tissues. Results are summarized in Table 2
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significantly higher in the cancerous tissues by approximately
273–375% (Po0.001).
Association with clinicopathological parameters
The association of MIC-1 mRNA level with clinicopathological
parameters in cancerous tissues is shown in Table 3. The
expression levels of MIC-1 gene did not show any significant
association with tumour stage (P¼0.69) and tumour grade
(P¼0.86). On the other hand, higher Gleason score (45 vs p5)
significantly associated with higher MIC-1 gene expression.
DISCUSSION
Prostate-specific antigen, also known as hK3, and its molecular
forms are the most useful tumour markers for the prostate cancer
and hK2, another member of the kallikrein gene family, may help
in reducing the number of unnecessary biopsies (Rittenhouse et al,
1998). Nevertheless, these serum biomarkers cannot accurately
predict the presence of prostate cancer, its aggressiveness or the
rate of postoperative PSA failure. New, improved biomarkers
might be necessary especially for Gleason 4/5 tumours (Stamey,
2001).
The MIC-1 gene was originally cloned from macrophages using
a subtraction-cloning strategy (Bootcov et al, 1997). This gene is a
member of the TGF-b superfamily. Other investigators discovered
this gene independently and gave it different names, such as
growth/differentiation factor-15 (GDF-15) (Bottner et al, 1999) and
prostate differentiation factor (PLAB) (Hromas et al, 1997; Thomas
et al, 2001).
Recently, the MIC-1 gene was found to be highly overexpressed
in human prostate (Welsh et al, 2001) and colorectal cancer
(Buckhaults et al, 2001) by microarray technology. To confirm
these results, and investigate the association with clinicopatholo-
gical parameters, we assessed the quantitative expression of MIC-1
Table 1 MIC-1 expression in pairs of noncancerous and cancerous
prostatic tissues
MIC expression Number of patients (%) P-value
a
Higher in cancer vs normal 58 (88) o0.001
Lower in cancer vs normal 8 (12)
aCalculated by McNemar test.
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Figure 1 MIC-1 mRNA expression as arbitrary units shown for 66
patients. The black box represents the level in cancerous tissue and the
connected white box the respective level of the nonmalignant tissue of the
same patient. The P-value was calculated by McNemar test.
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Figure 2 MIC-1 mRNA expression in cancerous and noncancerous
prostatic tissues. The horizontal lines indicate the median. The P-value was
calculated by the Mann–Whitney U-test.
Table 2 Descriptive statistics for MIC-1 expression (mRNA levels) in
noncancerous and cancerous prostatic tissues
Mean
a
Standard
error
a Median
a Range
a P-value
b
MIC, noncancer (N=66) 71 27 6.7 0.03–116
MIC, cancer (N=66) 264 106 32 0.21–5581 o0.001
% Increase
c 273% F 375%
aThese values are corrected for actin expression and are unitless ratios.
bCalculated
by the Wilcoxon’s signed rank test.
cCompared to cancer and assuming that the value
in noncancerous tissue is 100%.
Table 3 MIC expression in cancerous prostatic tissues from 66 patients
classified by stage of the disease, Gleason score and tumour grade
Total Mean
a Standard Error
a Median
a P-value
b
Stage
I/II 32 145 67 10 0.69
III 34 376 195 37
Gleason score
p5 21 117 90 9 0.004
45 40 373 167 54
Unknown 5
Grade
G1/2 39 114 50 22 0.86
G3 27 482 246 40
aThese values are corrected for actin expression and are unitless ratios.
bCalculated
by the Mann–Whitney U-test.
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noncancerous tissues using LightCycler
TM technology. Our results
showed that MIC-1 gene expression was significantly higher in
cancerous prostatic tissue than in noncancerous tissue. Higher
Gleason score (45) cancer expressed significantly more MIC-1
mRNA (Table 3). These data suggest that MIC-1 gene expression is
increased in cancer tissue, compared to normal tissue and its
expression is increased when the tumour progresses further. Thus,
the level of MIC-1 expression may be a marker of tumour
differentiation.
Transforming growth factor-b and its receptor were found to be
overexpressed in high-grade prostatic intraepithelial neoplasia in
the rat ventral prostate. It was reported that high expression of
TGF-b and its receptors enhance cancer growth and metastasis and
are associated with poor prognosis (Wong et al, 2000). Preopera-
tive plasma TGF-b levels are markedly elevated in men with
prostate cancer metastasis and are a strong predictor of biological
progression after surgery (Shariat et al, 2001). The macrophage
migration inhibitory factor (MIF) gene was reported to be elevated
in prostate cancer tissues and upregulation of this gene is
associated with serum level of MIF (Meyer-Siegler et al, 2002).
In conclusion, we report upregulation of the MIC-1 gene in
prostate cancer and in advanced and more aggressive prostatic
tumours. These data may indicate a possible role for the MIC-1
protein as a future diagnostic and prognostic biomarker.
Furthermore, the understanding of the biological function of
MIC-1 in prostate may help in delineating its role in prostatic
physiology and pathobiology.
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